<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245608</url>
  </required_header>
  <id_info>
    <org_study_id>DDRI/90.22</org_study_id>
    <nct_id>NCT01245608</nct_id>
  </id_info>
  <brief_title>Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.</brief_title>
  <acronym>PolyIran-L</acronym>
  <official_title>Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Golestan University of Medical Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the effects of a fixed dose combination of
      valsartan, hydrochlorothiazide, atorvastatin and aspirin (PolyPill) on prevention of
      cardiovascular events in adults older than 50.

      Various liver-related variables will also be recorded which will allow studying the effects
      of PolyPill on the liver and the effect of liver diseases such as nonalcoholic
      steatohepatitis on cardiovascular events and the protective effect of PolyPill.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2400 subjects will be randomly selected from participants of the Golestan Cohort Study (GCS)
      who are living in Gonbad and are over 50 years old. These subjects will be randomized to
      either receive PolyPill or no treatment.

      Those agreeing to the study will undergo additional measurements (in addition to the baseline
      measurements performed in the GCS) including liver-related tests such as liver enzyme levels,
      abdominal ultrasonography and liver stiffness measurement. Some additional tests such as
      color doppler ultrasonography of carotid vessels will also be performed.

      Subjects in the PolyPill arm who have no contraindication for the components of the pill will
      receive a single daily dose of PolyPill for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Cardiovascular Events</measure>
    <time_frame>5 years</time_frame>
    <description>The first occurrence of hospitalization for acute coronary syndrome (non-fatal myocardial infarction and unstable angina), fatal myocardial infarction, sudden death, new-onset heart failure, coronary artery revascularization procedures and stroke (fatal or non-fatal).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>5 years</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver enzyme levels</measure>
    <time_frame>5 years</time_frame>
    <description>AST, ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver stiffness</measure>
    <time_frame>5 years</time_frame>
    <description>As measured by fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>5 years</time_frame>
    <description>Pill count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat deposition</measure>
    <time_frame>5 years</time_frame>
    <description>Visceral Adipose Tissue thickness (VAT), Subcutaneous Adipose Tissue thickness (SAT) and carotid intima-media thickness (IMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Yearly follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Polypill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single daily dose of PolyPill and 6-monthly visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only 6-monthly visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polypill</intervention_name>
    <description>Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg</description>
    <arm_group_label>Polypill</arm_group_label>
    <other_name>PolyPill 4-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Being enrolled in Golestan Cohort Study

        Exclusion Criteria:

          -  Debilitating disease causing inability to comply

          -  Contraindications to any of the components of PolyPill

          -  Not consenting to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Malekzadeh, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shahin Merat, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Golestan Cohort Center</name>
      <address>
        <city>Gonbad</city>
        <state>Golestan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, Jafari E, Rakhshani N, Salahi R, Semnani S, Kamangar F, Abnet CC, Ponder B, Day N, Dawsey SM, Boffetta P, Malekzadeh R. Cohort Profile: The Golestan Cohort Study--a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010 Feb;39(1):52-9. doi: 10.1093/ije/dyp161. Epub 2009 Mar 30.</citation>
    <PMID>19332502</PMID>
  </reference>
  <reference>
    <citation>Ostovaneh MR, Poustchi H, Hemming K, Marjani H, Pourshams A, Nateghi A, Majed M, Navabakhsh B, Khoshnia M, Jaafari E, Mohammadifard N, Malekzadeh F, Merat S, Sadeghi M, Naemi M, Etemadi A, Thomas GN, Sarrafzadegan N, Cheng KK, Marshall T, Malekzadeh R. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial. Eur J Prev Cardiol. 2015 Dec;22(12):1609-17. doi: 10.1177/2047487314550803. Epub 2014 Sep 17.</citation>
    <PMID>25230980</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2010</study_first_submitted>
  <study_first_submitted_qc>November 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2010</study_first_posted>
  <last_update_submitted>March 3, 2018</last_update_submitted>
  <last_update_submitted_qc>March 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atorvastatin</keyword>
  <keyword>Aspirin</keyword>
  <keyword>nonalcoholic steatohepatitis</keyword>
  <keyword>nonalcoholic fatty liver disease</keyword>
  <keyword>antihypertensive agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

